Physician profile
Gregory Mula
NPI 1265437362
$4,158.82
in general payments reported to CMS, 2019-2025
26 companies · $830 in 2025
The $830 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $157 · 2021: $857 · 2022: $552 · 2023: $653 · 2024: $713 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,110.02 | 2019-2025 | |
| Celgene Corporation | $300.87 | 2021-2023 | Zeposia |
| Genzyme Corporation | $271.02 | 2024-2025 | |
| Gilead Sciences, INC. | $243.61 | 2019-2023 | |
| Pfizer INC. | $188.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.85 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.43 | 2019-2024 | Trulance, Plenvu |
| Ironwood Pharmaceuticals, INC | $104.64 | 2020-2022 | |
| Ardelyx, INC. | $97.43 | 2022-2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $86.93 | 2021 | |
| Intercept Pharmaceuticals, INC. | $54.33 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $47.55 | 2025 | Voquezna |
| Janssen Biotech, INC. | $44.57 | 2019-2025 | Tremfya |
| Merck Sharp & Dohme LLC | $43.04 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $41.74 | 2023 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.32 | 2021-2023 | Avsola |
| Olympus America INC. | $33.42 | 2019 | |
| Redhill Biopharma INC. | $31.90 | 2020-2022 | |
| Allergan, INC. | $24.84 | 2019 | |
| Alfasigma USA, INC. | $17.86 | 2022 | |
| Mauna Kea Technologies, INC. | $16.02 | 2024 | |
| Aimmune Therapeutics, INC. | $15.98 | 2025 | Zenpep |
| Pharmacosmos Therapeutics INC. | $14.12 | 2024 | Monoferric |
| Lilly USA, LLC | $14.07 | 2025 | Omvoh |
| Evoke Pharma, INC. | $13.36 | 2023 | Gimoti |
| Qol Medical, LLC | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.